Cat. No. 0916
Chemical Name: (S)-(-)-3-Bromo-N-[(1-ethyl-2-pyrro
Biological ActivityDopamine D2 receptor antagonist showing selectivity over D3 and D4 receptors (Ki values are ~ 300, ~ 1600, and ~ 2800 nM for D2, D3 and D4 receptors respectively). Exhibits antipsychotic activity in vivo with no extrapyramidal side effects. 50-fold more potent than sulpiride in antagonising the effects of apomorphine in the rat.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Sedvall (1990) Development of a new antipsychotic remoxipride. Acta Psychiatr.Scand.Suppl. 358 1. PMID: 1978466.
Mohell et al (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur.J.Pharmacol. 238 121. PMID: 8405075.
Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID: 7940991.
Ahlenius et al (1997) In vivo effects of remoxipride and aromatic ring metabolites in the rat. J.Pharmacol.Exp.Ther. 283 1356. PMID: 9400011.
If you know of a relevant citation for this product please let us know.
Keywords: Remoxipride hydrochloride, supplier, selective, D2-like, antagonists, dopamine, non-selective, receptor, antagonist, dopaminergic, d2